Mirae Asset Global Investments Co. Ltd. Has $92,000 Position in Teva Pharmaceutical Industries Ltd. $TEVA

Mirae Asset Global Investments Co. Ltd. raised its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 15.0% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,474 shares of the company’s stock after acquiring an additional 715 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Teva Pharmaceutical Industries were worth $92,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in TEVA. GAMMA Investing LLC lifted its stake in Teva Pharmaceutical Industries by 804.7% in the first quarter. GAMMA Investing LLC now owns 67,474 shares of the company’s stock valued at $1,037,000 after acquiring an additional 60,016 shares during the last quarter. Yousif Capital Management LLC lifted its stake in Teva Pharmaceutical Industries by 1.9% in the first quarter. Yousif Capital Management LLC now owns 55,986 shares of the company’s stock valued at $861,000 after acquiring an additional 1,033 shares during the last quarter. Handelsbanken Fonder AB acquired a new stake in Teva Pharmaceutical Industries in the first quarter valued at $243,000. Fifth Third Bancorp lifted its stake in shares of Teva Pharmaceutical Industries by 17.4% during the 1st quarter. Fifth Third Bancorp now owns 21,985 shares of the company’s stock worth $338,000 after buying an additional 3,265 shares during the last quarter. Finally, Foster Victor Wealth Advisors LLC acquired a new stake in shares of Teva Pharmaceutical Industries during the 1st quarter worth about $192,000. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Price Performance

NYSE:TEVA opened at $20.01 on Monday. Teva Pharmaceutical Industries Ltd. has a 52 week low of $12.47 and a 52 week high of $22.80. The firm has a market cap of $22.95 billion, a price-to-earnings ratio of -125.04, a P/E/G ratio of 1.10 and a beta of 0.71. The firm’s 50-day simple moving average is $18.51 and its 200 day simple moving average is $16.97. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.77 and a current ratio of 1.06.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Wednesday, July 30th. The company reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.02. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The business had revenue of $4.18 billion for the quarter, compared to analyst estimates of $4.34 billion. During the same period last year, the firm earned $0.61 earnings per share. Teva Pharmaceutical Industries’s revenue for the quarter was up .3% compared to the same quarter last year. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. As a group, sell-side analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current year.

Insider Transactions at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, insider Placid Jover sold 6,053 shares of the firm’s stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $15.16, for a total value of $91,763.48. Following the transaction, the insider directly owned 6,774 shares of the company’s stock, valued at $102,693.84. This trade represents a 47.19% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Eric A. Hughes sold 52,742 shares of the firm’s stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $15.16, for a total transaction of $799,568.72. The disclosure for this sale can be found here. 0.49% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on TEVA. JPMorgan Chase & Co. raised their target price on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock an “overweight” rating in a research note on Friday, October 3rd. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Weiss Ratings restated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Wednesday, October 8th. Finally, UBS Group raised their target price on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock a “buy” rating in a research note on Wednesday, September 24th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $25.57.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.